Cogent Biosciences, Inc. (COGT) Stock Score, Valuation & Financial Research

Cogent Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for COGT

Cogent Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 30.38. These figures are a research snapshot, not a buy or sell recommendation.

What Cogent Biosciences, Inc. does

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cogent Biosciences is a clinical-stage biotechnology company that does not currently generate product revenue. Its business model focuses on the research and development of precision therapies for genetically defined diseases, funded primarily through capital raises and equity offerings to support clinical trials and regulatory submissions.

Products and services

  • The company is developing bezuclastinib, a selective KIT inhibitor, for the treatment of Non-Advanced Systemic Mastocytosis, Advanced Systemic Mastocytosis, and Gastrointestinal Stromal Tumors, alongside a research pipeline targeting PI3Kα, KRAS, and JAK2 mutations.

Customer types

Patients with genetically defined diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Positive registrational trial results for bezuclastinib Source
  • Strong cash position to fund operations Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

COGT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 30.38
Market capitalization:
5.19B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -377.18M
Free cash flow:
USD -266M
Cash:
USD 181.17M
Total debt:
USD 244.26M
EPS:
USD -2.31

What stands out

  • Free cash flow is USD -266M, negative for the stored period.
  • The balance sheet shows USD 181.17M of cash versus USD 244.26M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 63.09M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for COGT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can COGT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does COGT's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for COGT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of COGT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research COGT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.